PHARMARON BEIJING CO., LTD. Funds and ETFs Pharmaron Beijing Co., Ltd.
Equities
300759
CNE100003JW4
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.25 CNY | -6.73% |
|
-8.42% | -33.57% |
ETFs positioned on Pharmaron Beijing Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.17% | 2 M€ | -19.34% | - | |
| 0.13% | 35 M€ | -5.85% | - | |
| 0.10% | 3 M€ | +0.75% | - | |
| 0.06% | 2 M€ | -.--% | ||
| 0.05% | 4 M€ | -11.56% | ||
| 0.03% | 7 M€ | -.--% | - | |
| 0.01% | 112 M€ | +4.57% | - | |
| 0.01% | 2,867 M€ | +5.95% | - | |
| 0.01% | 454 M€ | +5.22% | - | |
| 0.01% | 153 M€ | +5.46% | - | |
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 7 M€ | +5.77% | - | |
| 0.00% | 34 M€ | +4.20% | - | |
| 0.00% | 15 M€ | +14.62% |
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).
Calendar
2024-06-06
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
19.25
CNY
Average target price
24.15
CNY
Spread / Average Target
+25.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.57% | 4.29B | |
| +48.64% | 56.65B | |
| -6.44% | 39.44B | |
| +37.26% | 39.03B | |
| +14.28% | 26.75B | |
| -11.17% | 26.86B | |
| -21.40% | 19.03B | |
| +25.64% | 12.26B | |
| +0.96% | 12.28B | |
| +27.04% | 12.04B |
- Stock Market
- Equities
- 300759 Stock
- Funds and ETFs Pharmaron Beijing Co., Ltd.
